Product logins

Find logins to all Clarivate products below.


Hospital-Treated Infections | TreatmentTrends | US | 2015

Hospital emergency departments (EDs) are sites where the majority of patients with serious, acute bacterial infections initially seek medical care. As such, these sites often represent the initial treatment setting, where patients receive the first dose of antibiotic(s) and are triaged for possible hospital admission or subsequent therapy in the outpatient setting. Therefore, EDs play an important role in initial treatment/brand selection. This report examines the current trends in management and antibiotic treatment of patients presenting to EDs with bacterial infections, and it examines their management and treatment through hospital inpatient and/or outpatient care following discharge. The report evaluates prescribing practices and guidelines in the ER, in the inpatient setting, and upon patient discharge.

Related Market Assessment Reports

Report
Hyperkalemia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hyperkalemia (US)
Hyperkalemia is a potentially life-threatening condition characterized by a serum potassium concentration that exceeds 5.5 mEq/L. Despite various guidelines, a universally accepted consensus on the…
Report
Primary Biliary Cholangitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Primary Biliary Cholangitis (US)
Primary biliary cholangitis (PBC) is a rare autoimmune liver disease characterized by inflammation and progressive damage to intrahepatic bile ducts, leading to bile buildup, followed by…
Report
Squamous Cell Carcinoma of the Head and Neck – Landscape & Forecast – Disease Landscape & Forecast (G7)
Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…
Report
Systemic Lupus Erythematosus – Current Treatment – Treatment Algorithms: Claims Data Analysis – Systemic Lupus Erythematosus (US)
Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organ systems. SLE symptoms range from general malaise to serious CNS and renal manifestations. Hydroxychloroquine…
Report
Chimeric Antigen Receptor (CAR) T-Cell Therapy – Access & Reimbursement – Access & Reimbursement – Chimeric Antigen Receptor (CAR) T-Cell Therapy (US)
Ever since Novartis’s Kymriah became the first chimeric antigen receptor (CAR) T-cell therapy approved by the FDA for a cancer indication (acute lymphoblastic leukemia) in 2017, this class of…